Company Overview
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
Why Investors Should Care
Trades at a P/E of 12.2, below the sector median of 24.8.
Maintains a net profit margin of 20.7%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $370.50M (-6.2% YoY); net profit $93.83M.
- Trailing 12 Months Year-on-year growth — revenue +-0.0%, earnings -31.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -6.6%, profit CAGR -16.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -6.57% |
| 1 Year: | -0.00% |
Compounded Profit Growth
| 5 Years: | -16.56% |
| 1 Year: | -31.00% |
Stock Price Performance
| 1 Year: | +1.09% |
| 6 Months: | +11.44% |
| 3 Months: | +9.70% |
| 1 Month: | -3.27% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)43.14 · Neutral
P/E of 12.24 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 20.7%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -6.6% CAGR over 5 years.
- Earnings shrank at -16.6% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INMD InMode Ltd. PHARMA | 14.81 | 12.24 | $852.23M | 0.00% | 12.27% | 12.33% | -6.57% | -16.56% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 77.87M | 95.60M | 93.17M | 103.85M | 82.02M |
| Cost of Revenue | 16.96M | 19.15M | 20.86M | 22.55M | 20.46M |
| Gross Profit | 60.91M | 76.45M | 72.31M | 81.30M | 61.55M |
| Operating Expenses | 45.29M | 53.57M | 51.41M | 55.31M | 51.50M |
| Operating Income | 15.62M | 22.88M | 20.90M | 25.99M | 10.06M |
| EBITDA | 15.79M | 23.07M | 21.05M | 26.16M | 10.23M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | 22.48M | 30.94M | 25.62M | 31.29M | 14.35M |
| Tax Provision | 4.28M | 4.20M | 3.75M | 4.27M | 2.79M |
| Net Income | 18.20M | 26.74M | 21.86M | 27.02M | 11.56M |
| Diluted EPS | 0.26 | 0.42 | 0.34 | 0.42 | 0.18 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 454.27M | 492.05M | 394.82M | 370.50M |
| Cost of Revenue | - | 73.48M | 80.71M | 77.75M | 79.53M |
| Gross Profit | - | 380.79M | 411.34M | 317.07M | 290.97M |
| Operating Expenses | - | 182.93M | 215.68M | 204.53M | 205.58M |
| Operating Income | - | 197.85M | 195.66M | 112.53M | 85.39M |
| EBITDA | - | 198.53M | 196.28M | 113.26M | 86.08M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | 201.47M | 217.27M | 143.47M | 110.33M |
| Tax Provision | - | 39.95M | 19.35M | -37.81M | 16.50M |
| Net Income | - | 161.52M | 197.92M | 181.28M | 93.83M |
| Diluted EPS | - | 1.89 | 2.30 | 2.25 | 1.43 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 644.41M | 863.29M | 785.67M | 766.43M |
| Current Assets | - | 629.37M | 845.33M | 714.45M | 698.62M |
| Cash & Equivalents | - | 97.54M | 144.41M | 155.33M | 302.54M |
| Inventory | - | 39.90M | 45.09M | 59.55M | 74.05M |
| Receivables | - | 27.00M | 42.36M | 36.34M | 43.50M |
| Total Liabilities | - | 89.79M | 75.91M | 81.85M | 83.23M |
| Current Liabilities | - | 82.02M | 64.14M | 69.85M | 70.74M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 4.96M | 9.02M | 7.82M | 8.23M |
| Total Equity | - | 554.62M | 787.37M | 703.81M | 683.20M |
| Shares Outstanding | - | 84.52M | 85.96M | 87.58M | 88.33M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 181.58M | 176.83M | 132.66M | 85.26M |
| Investing Cash Flow | - | -109.47M | -136.06M | 162.21M | 186.03M |
| Financing Cash Flow | - | -41.09M | 5.50M | -282.77M | -126.06M |
| Capital Expenditure | - | -1.57M | -705.00K | -669.00K | -972.00K |
| Free Cash Flow | - | 180.00M | 176.12M | 132.00M | 84.28M |
| Net Change in Cash | - | 31.02M | 46.27M | 12.10M | 145.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 83.8% | 83.6% | 80.3% | 78.5% |
| Operating Margin % | - | 43.6% | 39.8% | 28.5% | 23.0% |
| Net Margin % | - | 35.6% | 40.2% | 45.9% | 25.3% |
| ROE % | - | 29.1% | 25.1% | 25.8% | 13.7% |
| ROCE % | - | 35.2% | 24.5% | 15.7% | 12.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Doma Perpetual Capital Management LLC | 4.75% | 2.73M | $39.19M |
| 2 | Acadian Asset Management. LLC | 4.50% | 2.58M | $37.08M |
| 3 | Blackrock Inc. | 4.34% | 2.50M | $35.81M |
| 4 | Renaissance Technologies, LLC | 4.16% | 2.39M | $34.32M |
| 5 | Menora Mivtachim Holdings Ltd. | 3.55% | 2.04M | $29.27M |
| 6 | Steel Partners Holdings, LP | 3.18% | 1.83M | $26.24M |
| 7 | Millennium Management Llc | 3.05% | 1.75M | $25.14M |
| 8 | Morgan Stanley | 1.94% | 1.12M | $16.00M |
| 9 | Systematic Financial Management, L.P. | 1.77% | 1.02M | $14.58M |
| 10 | Jupiter Topco LLC | 1.68% | 966.02K | $13.86M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INMD
Bank of America Corp DE Sells 236,577 Shares of InMode Ltd. $INMD - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOeWpCMXBPMHhMaElHUVpoNmFXM0ljN1RMR2Z0US1DUG0tM1JtSEFmVVI0WEdxNnBaZXJ6NXQxSGZWb3ktNDh0TGlaeC1URmlFd1BFeDVZLTlGOTdYNXVGQlJMQXlnMW5JMkdfVF9XVHdzSEtXa0ZYdml4SmViREtIVHJrcVdWbEpvaDNkeE…
InMode Shares Jump After Steel Partners Tables Higher Takeover Proposal (INMD) - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQd3V3a3piSWNNbUdFekJIOF9TNjNGczMyelV2VmFqZThBZHV2bUxTYmJzQ3pZRklxYnVub3U5RHNWMjJXRS1yVlhpRXNTMnJkOHVKZGFNUm91SlJUek90emtYdGtXS1NXNmR2SHJXWTNYY2VvY0xvb0c0TW1YT21HdnlROWRuNDNtRTEzd1…
InMode to Report Second Quarter 2026 Financial Results on August 5, 2026, Expects Q2 Revenue Between $95.2M-$95.4M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M - PR Newswire
<a href="https://news.google.com/rss/articles/CBMixAJBVV95cUxOMGpQcTRlelNPOHJvLXkzd0tiQ3Z5Uk43cXVEbEFyYnJaTXVSODNGdk5PdWg5Ty1UUUI5NjFsNnFvNld6SHN5aGVWeTVSWEhDMTlfbDM0eF90TElvU0QyVmcteGk0NTduU2tXcHZ0aWZXdnpKSEJ3Y2M1QUJlNjBTZnBnRWN6YUR6cDVDbj…
INMD Stock Heads For Best Day In Nearly Six Months – How Does The Latest Takeover Proposal Compare To Steel Partners’ Offer? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPSHlvdk4yT3NRSnF0enlwRGRWUGlVZXpzNk9qZVhuQndBMngydUYzdnptTHVkS3VzanV1S2VRQ0hUekpqcXZ0YWVZSHZGLVpSbTdCRGxGS2dOdnhIZVNSeFJKTlgtendFTlFoUndSRVBUMkFLbERHM0NlcUlOZXB3M2N2OEQxempsSnA0Sj…
INMD - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1NNWxFTVozSXR4OTNsUU9sUUMxRGlqcE83ajg1azdwSmFHRlZVNTVjX0N1SDg3OWdJMV9aYnc0V3NNc19PTkE?oc=5" target="_blank">INMD</a> <font color="#6f6f6f">Finviz</font>…
InMode buyout bid gets pushback from 4.63% holder DOMA - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOb1Q3UUwxMkdCN2Z1bHZzV2dqdHRpZ0dpS3FUdnJhdklmY1c0eXhyQk1hYUZLRWNiRkhlcDZkaVJHcjFXNkJDT0gyOTFweUw4cHBIZWFXYnhiUU02VDRZcms0S3Y5UUQwNzZWbEEtZUNLWER6ZTRmWmJCZmVma2JvNkV0ZWZJc0hvTk9CUj…
INMD — Frequently Asked Questions
What is the current share price of InMode Ltd. (INMD)?
As of 2026-09-19 21:16 PDT, InMode Ltd. (INMD) trades at $14.81 on NasdaqGS. Its 52-week range is $12.76 to $16.62.
What is the market capitalisation of INMD?
InMode Ltd. (INMD) has a market capitalisation of $852.23M on NasdaqGS.
What is the P/E ratio of INMD?
INMD trades at a trailing price-to-earnings (P/E) ratio of 12.24. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.34.
What is the return on equity (ROE) of INMD?
INMD has a return on equity (ROE) of 12.33%. Its return on capital employed (ROCE) is 12.27%.
Is INMD a good stock to buy?
This page provides a data-driven analysis of InMode Ltd. (INMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.